New study tests aggressive BP management to protect heart and kidneys in cancer patients
NCT ID NCT04467021
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This phase II trial tests whether intensive blood pressure management (targeting systolic BP below 120 mmHg) is better than standard care (below 140 mmHg) for patients with advanced kidney or thyroid cancer starting anti-angiogenic TKI therapy. The study enrolls 61 participants and measures blood pressure differences over 6 months. The goal is to find the safest way to manage BP during cancer treatment to reduce cardiovascular and kidney risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin, 54143, United States
-
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311, United States
-
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024, United States
-
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142, United States
-
Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin, 53209, United States
-
Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin, 53226, United States
-
Aurora Cancer Care-Racine
Racine, Wisconsin, 53406, United States
-
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105, United States
-
Aurora Health Care Germantown Health Center
Germantown, Wisconsin, 53022, United States
-
Aurora Medical Center in Summit
Summit, Wisconsin, 53066, United States
-
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215, United States
-
Aurora Saint Luke's South Shore
Cudahy, Wisconsin, 53110, United States
-
Aurora Sinai Medical Center
Milwaukee, Wisconsin, 53233, United States
-
Aurora West Allis Medical Center
West Allis, Wisconsin, 53227, United States
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, 10461, United States
-
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin, 54904, United States
-
Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin, 53081, United States
-
Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin, 54241, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
intensive blood pressure management (target systolic BP <120 mmHg)
What this could lead to
If successful, this could show that aggressive blood pressure control reduces heart and kidney complications in cancer patients on certain therapies.
What could go wrong
This is a small, early-phase study (61 participants) focused on feasibility, not hard outcomes. Results may not apply broadly, and intensive BP lowering carries risks like dizziness or fainting.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.